Richmond, VANCT07710534Now EnrollingIRB Ready

Relapsed / Refractory AML Clinical Trial in Richmond, VA

Access cutting-edge relapsed / refractory aml treatment through this phase 2 clinical trial at a research site in Richmond. Study-provided care at no cost to qualified participants.

Sponsored by Virginia Commonwealth University

Quick Self-Assessment

See if you qualify for this Richmond location

Preparing your pre-screening questions…

Expert Care in Richmond

Access relapsed / refractory aml specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related relapsed / refractory aml treatment provided free

Apply for This Richmond Location

Check if you qualify for this relapsed / refractory aml clinical trial in Richmond, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Richmond

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Richmond site if eligible
  4. 4Begin participation

About This Relapsed / Refractory AML Study in Richmond

This is a single-center randomized phase 2 open-label clinical trial.

Sponsor: Virginia Commonwealth University

Who Can Participate

Inclusion Criteria

Age ≥18 years at time of enrollment
Diagnosis of one of the following by World Health Organization (WHO) International Consensus Classification (ICC) criteria as determined by local assessment:
Relapsed/ refractory acute myeloid leukemia (R/R AML) as defined by ≥5% marrow blasts or unequivocal, measurable extramedullary disease
High Risk Myelodysplastic Syndrome (HR-MDS) (high/very high risk MDS by Revised International Prognostic Scoring System (IPSS-R) or Molecular International Prognostic Scoring System (IPSS-M)
high-risk accelerated-phase myeloproliferative neoplasm (HR/AP-MPN) defined by ≥10% blasts in blood or bone marrow
Eastern Cooperative Oncology Group (ECOG) Performance status 0-3
White blood cell (WBC) count ≤25 × 109/Liter (L) (cytoreduction with hydroxyurea or steroids is allowed to achieve this)
Aspartate Aminotransferase (AST)/ Alanine Aminotransferase (ALT) ≤3 × upper limit of normal (ULN) (≤5 × ULN if due to leukemic involvement)
Total bilirubin ≤2 × ULN (unless the elevation is due to Gilbert's or hemolysis)
Creatinine clearance ≥ 30 milliliters / minute (mL/min)
Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of non-childbearing potential are those who have had a hysterectomy or bilateral oophorectomy, or who have completed menopause (no menses for at least one year and age ≥65 or follicle-stimulating hormone levels in the menopausal range).
Subjects and their partners with reproductive potential must agree to use effective contraceptive measures during the study and for 3 months after the last dose of study treatment. Effective contraception includes methods such as oral contraceptives or double-barrier method.

Exclusion Criteria

Prior use of hypomethylating agent and venetoclax in combination (Note, use of hypomethylating agent and/or venetoclax separately in alternative combinations with other drugs is allowed)
Inability to tolerate oral therapies, or medical co-morbidities that significantly impact parenteral absorption
Acute promyelocytic leukemia myeloproliferative neoplasm (MPN) with the Philadelphia chromosome translocation (BCR:ABL) translocation
Clinically significant cardiovascular disease as defined by unstable angina
New York Heart Association class III/IV congestive heart failure
Treatment with any investigational drug or therapy within 2 weeks of study treatment or 5 half-lives before the first dose of study treatment, whichever is shorter
Known hypersensitivity to azacitidine, venetoclax, decitabine or cedazuridine
Cytotoxic chemotherapy or prior azacitidine or decitabine within 2 weeks of first dose of study treatment
Concurrent use of AML/MDS/MPN therapies including lenalidomide, erythropoietin, luspatercept, cytotoxic chemotherapies, targeted agents, etc Note: hydroxyurea is allowed in Cycle 1 if necessary for cytoreduction and/or cytarabine not exceeding a maximum dose of 1 gram per meter squared (g/m2) in Cycle 1 is also allowed for cytoreduction
Uncontrolled intercurrent illness or infection (those with controlled HIV, hepatitis, or other chronic infections are eligible)
Untreated central nervous system disease
Pregnancy or breastfeeding
Other active malignancy requiring systemic therapy during duration of trial or otherwise would confound endpoints (eg, second malignancy present where survival is expected to be less than 6 months)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Richmond?

Yes, this clinical trial (NCT07710534) has an active research site in Richmond, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Relapsed / Refractory AML Treatment Options in Richmond, VA

If you're searching for relapsed / refractory aml treatment options in Richmond, VA, this clinical trial (NCT07710534) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Richmond research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced relapsed / refractory aml specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all relapsed / refractory aml clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Richmond, VA

See all leukemia clinical trials recruiting in Richmond — not just this study.

Browse Leukemia Trials in Richmond →

Browse More Trials by Condition

Leukemia TrialsAcute Myeloid Leukemia TrialsRheumatoid Arthritis TrialsAntiphospholipid Syndrome TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Richmond?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Richmond, VA